These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34152529)

  • 1. The Predictive Value of Lp(a) for Adverse Cardiovascular Event in ACS Patients With an Achieved LDL-C Target at Follow Up After PCI.
    Ren Y; Pan W; Li X; Wang S; Lv H; Yu Y; Wang M; Xia Y; Yin D
    J Cardiovasc Transl Res; 2022 Feb; 15(1):67-74. PubMed ID: 34152529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: A retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients.
    Wang Y; Yan BP; Nichol MB; Tomlinson B; Lee VWY
    Int J Cardiol; 2017 Dec; 249():18-24. PubMed ID: 29121725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between lipoprotein(a) and revascularization after percutaneous coronary intervention in type 2 diabetes mellitus patients with acute coronary syndrome.
    Hao Y; Yang Y; Wang Y; Li J
    Curr Med Res Opin; 2022 Oct; 38(10):1663-1672. PubMed ID: 35575139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between small dense low density lipoprotein and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Zhang J; He L
    BMC Cardiovasc Disord; 2021 Apr; 21(1):169. PubMed ID: 33845772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels.
    Zhu L; Zheng J; Gao B; Jin X; He Y; Zhou L; Huang J
    BMC Cardiovasc Disord; 2022 Apr; 22(1):171. PubMed ID: 35428179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.
    Zhong Z; Hou J; Zhang Q; Zhong W; Li B; Li C; Liu Z; Yang M; Zhao P
    Lipids Health Dis; 2019 Feb; 18(1):40. PubMed ID: 30711009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes.
    Gencer B; Rigamonti F; Nanchen D; Vuilleumier N; Kern I; Aghlmandi S; Klingenberg R; Räber L; Auer R; Carballo D; Carballo S; Heg D; Windecker S; Lüscher TF; Matter CM; Rodondi N; Mach F
    Eur J Clin Invest; 2019 Jul; 49(7):e13117. PubMed ID: 30937890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy.
    Matsushita K; Hibi K; Komura N; Kimura Y; Matsuzawa Y; Konishi M; Maejima N; Iwahashi N; Kosuge M; Ebina T; Tamura K; Kimura K
    J Cardiol; 2020 Jul; 76(1):66-72. PubMed ID: 32037254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.
    Konishi H; Miyauchi K; Shitara J; Endo H; Wada H; Doi S; Naito R; Tsuboi S; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
    Am J Cardiol; 2016 Dec; 118(12):1781-1785. PubMed ID: 27712648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Low-density lipoprotein cholesterol target goal attainment rate and related factors in patients with acute coronary syndrome after percutaneous coronary intervention].
    Zhang B; Dong X; Zhang Y; Huang R; Yin D; Zheng Z; Liu Y; Zhu H; Zhou X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Apr; 42(4):290-4. PubMed ID: 24924454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS).
    Afshar M; Pilote L; Dufresne L; Engert JC; Thanassoulis G
    J Am Heart Assoc; 2016 Apr; 5(4):. PubMed ID: 27108248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention.
    Konishi H; Miyauchi K; Tsuboi S; Ogita M; Naito R; Dohi T; Kasai T; Tamura H; Okazaki S; Isoda K; Daida H
    Int J Cardiol; 2016 Feb; 205():50-53. PubMed ID: 26710333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
    Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
    Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of lipoprotein(a) in patients undergoing percutaneous coronary intervention modified by low density lipoprotein cholesterol.
    Xu N; Yuan D; Yao Y; Jiang L; Xu J; Tang X; Song Y; Gao L; Chen J; Song L; Zhao X; Chen J; Yang Y; Xu B; Gao R; Yuan J
    Clin Chim Acta; 2023 Feb; 540():117217. PubMed ID: 36610466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
    Bittner VA; Szarek M; Aylward PE; Bhatt DL; Diaz R; Edelberg JM; Fras Z; Goodman SG; Halvorsen S; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Moriarty PM; Moryusef A; Pordy R; Roe MT; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
    J Am Coll Cardiol; 2020 Jan; 75(2):133-144. PubMed ID: 31948641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Value of Lipoprotein-Associated Phospholipase A
    Yang L; Wang H; Zhang Y; Han T; Wang W
    Clin Appl Thromb Hemost; 2018 Jul; 24(5):822-827. PubMed ID: 29121808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention.
    Matsumoto I; Miyake Y; Mizukawa M; Takagi Y
    Circ J; 2011; 75(4):905-10. PubMed ID: 21325724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins.
    Takahashi D; Wada H; Ogita M; Yasuda K; Nishio R; Takeuchi M; Shitara J; Tsuboi S; Dohi T; Suwa S; Miyauchi K; Daida H; Minamino T
    Am J Cardiol; 2022 Apr; 168():11-16. PubMed ID: 35067346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.